Bidridistrogene xeboparvovec

西哌比瑞基

Report date: 2024/02/27 17:50:34

Base Information

Drug NameBidridistrogene xeboparvovec
Drug Alias NamescAAVrh74.tMCK.hSGCBscAAVrh74.MHCK7.hSGCBrAAVrh74.MHCK7.hSGCBrAAVrh74.MHCK7.SGCBMYO-101 +[6] 
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAVrh74 vector
Mechanisms of ActionBeta-sarcoglycan gene transference
TargetsBeta-sarcoglycan
Therapy Area/IndicationsLimb girdle muscular dystrophy 2EMuscular Dystrophies, Limb-Girdle
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesItaly +[6] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesNationwide Children'S Hospital
China Registration ClassN/A

Develop Information

Active CompaniesMyonexus Therapeutics IncSarepta Therapeutics IncNationwide Children'S Hospital
Inactive CompaniesN/A
Active IndicationsMuscular Dystrophies, Limb-Girdle
Inactive IndicationsLimb girdle muscular dystrophy 2E

Other Information

ATC CodeN/A
Related LinksDrugBank